ClinTrialsGov Registered Clinicals Trials ID
Status
1
Recruiting
Clinical Study Name Safety and Efficacy Study of Autologous Bone Marrow Aspirate Concentrate for No-‐Option Critical Limb Ischemia Conditions: Interventions:
2
Completed
Conditions: 3
Completed
Conditions: 4
Active, not recruiting
Condition:
5
Recruiting
Condition: 6
Recruiting
Condition: 7
Active, not recruiting
Conditions:
8
Completed
Condition: 9
Completed
Condition: 10
Completed
Intervention: 11
Completed
Condition: 12
Recruiting
Conditions: 13
Recruiting
Condition: 14
Completed
Condition: Completed
Condition: Unknown †
Conditions: Completed
Condition: Active, not recruiting
Conditions:
Recruiting
Condition: Recruiting
Conditions: Not yet recruiting
Completed
Condition:
Interventions: Completed
Interventions: Recruiting
Condition: Active, not recruiting
Completed
Condition:
Conditions: Unknown †
Condition: Active, not recruiting
Condition: Completed
Condition: Recruiting
Conditions: Active, not recruiting
Completed
Condition:
Condition: Completed
Conditions: Unknown †
Condition: Completed
Germany
II
Culturem MSC
India
II
ASC-‐cultured
Spain
II
BMMNC
Czech
II
FGF
SANOFI
II
PBMNC-‐GSF
India
II
BMMNC
Iran
I
BMMNC
Arteriocyte,USA
II
ASC-‐SVF
Kasiak Research,India
II
BMMNC
Biomet Biologics
III
HGF
AnGES
II
CD34+
USA
II
JVS 100
JUVENTAS
II
BMMNC,ADSC
Spain
III
BMMNC
HARVEST
II
ALDH-‐BM,BMMNC
ALDAGEN
I
BMMNC
Denmark
II
BMMNC
India
II
BMMNC
Aastrom Bioscience
II
HGF
AnGES
II
BMMNC
HARVEST
I
BMMNC
HARVEST
I
Placenta MSC
Pluristem
I
BMMNC
France
II
BMMNC
Germany
Ischemic Ulcer Biological: 4times injection; Biological: stem cell transplantation
Critical Limb Ischemia (CLI); Peripheral Vascular Disease (PVD) Device: Magellan®
Critical Limb Ischemia Biological: Autologous Stromal Vascular Fraction (SVF); Biological: Autologous Adipose Derieved MSCs; Other: Control
Critical Limb Ischemia; Peripheral Arterial Disease; Peripheral Vascular Disease Device: Bone marrow concentration device; Procedure: Placebo procedure (sham) Critical Limb Ischemia Genetic: AMG0001 Peripheral Artery Disease; Peripheral Vascular Disease; Critical Limb Ischemia Biological: CD34-positive cells; Biological: Saline and 5% autologous plasma Critical Limb Ischemia Biological: JVS-100(4 mg) or placebo/8 injections; Biological: JVS-100(8 mg) or placebo/8 injections; Biological: JVS-100(8 mg) or placebo/16 injections; Biological: JVS-100(16 mg) or placebo/16 injections
Critical Limb Ischemia (CLI) Drug: Stem cell infusion Critical Limb Ischemia Device: BMAC injection; Device: Placebo injection Critical Limb Ischemia; Peripheral Arterial Disease; Peripheral Vascular Disease Procedure: ALDH-br bone marrow cells vs. mononuclear bone marrow cells Ischemia Procedure: Stem cell implantation
Critical Limb Ischemia Other: Autologous Bone Marrow Mononuclear cells
Peripheral Arterial Disease Biological: autologous bone marrow cells; Biological: electrolyte solution (without cells) Critical Limb Ischemia; Vascular Diseases; Peripheral Arterial Disease Genetic: HGF Plasmid Ischemia Device: Harvest Smartprep2 BMAC System; Device: SmartPReP2 BMAC System; Biological: placebo Arterial Occlusive Diseases Device: centrifuge, laboratory, tabletop (SmartPReP2 BMAC System)
Peripheral Artery Disease; Peripheral Vascular Disease; Critical Limb Ischemia Biological: PLX-PAD
Cell Therapy With Bone Marrow Mononuclear Cells in Critical Leg Ischemia (CLI) Intervention:
35
Bone marrow-‐expanded
Procedure: will receive G-CSF and peripheral blood derived mononuclear cells; Drug: G-CSF; Drug: Standard Therapy
Safety of Intramuscular Injections (IM) of Allogeneic PLX-‐PAD Cells for the Treatment of Critical Limb Ischemia (CLI) Intervention:
34
II
Diabetic Foot; Critical Limb Ischemia; Leg Ulcers
Feasability Study of Autologous Bone Marrow Aspirate Concentrate for Treatment of CLI Intervention:
33
Italy
Drug: XRP0038 (NV1FGF)
Study of Autologous Bone Marrow Concentrate for the Treatment of Critical Limb Ischemia (CLI) Interventions:
32
CD133+ autologní
Severe Peripheral Artery Occlusive Disease.
A Phase IIB Pilot Study of a Modified Dosage Regimen of AMG0001 in Subjects With Critical Limb Ischemia Intervention:
31
II
Procedure: BMAC application in Critical Limb Ischemia
Use of Ixmyelocel-‐T (Formerly Vascular Repair Cells [VRC]) in Patients With Peripheral Arterial Disease to Treat Critical Limb Ischemia Interventions:
30
Spain
Critical Limb Ischemia
Safety and Efficacy of Autologous Bone Marrow Mononuclear Cells in Patients With Severe Critical Limb Ischemia Intervention:
29
ADSC
Other: Intramuscular injection of a suspension of adult mesenchymal stem cells derived
Treatment of Severe Limb Ischemia With Autologous Bonemarrow Derived Mononuclear Cells Intervention:
28
II
Nonrevascularizable Critical Ischemia of the Lower Limbs
ALD-‐301 for Critical Limb Ischemia, Randomized Trial Intervention:
27
SALUS-‐Hungary
Biological: Allogeneic Mesenchymal Stem Cells; Other: Standard protocol of care
Bone Marrow Aspirate Concentrate (BMAC) for Treatment of Critical Limb Ischemia (CLI) Interventions:
26
PBMNC-‐Cultured
Critical Limb Ischemia; Buerger's Disease
Clinical Trial I/II Opened, Randomized and Controlled for the Study of the Use of Stem Cells Therapy in Insulinized Diabetic Patients Type 2 With Critical Ischemia in Lower Limbs (CLI): Study of the Needs of Insulin Intervention:
25
II
Biological: tissue repair cells (TRC); Biological: bone marrow stem cells (BMC)
Study to Evaluate the Safety and Efficacy of JVS-‐100 Administered to Adults With Critical Limb Ischemia Condition:
24
Spain
Diabetic Foot
Injection of Autologous CD34-‐Positive Cells for Critical Limb Ischemia Conditions:
23
ADSC
Other: Endothelial progenitor cells intramuscular implant
Safety and Efficacy of Subjects With Critical Limb Ischemia Intervention:
22
II
Critical Limb Ischemia
Safety and Efficacy Study of Autologous Concentrated Bone Marrow Aspirate (cBMA) for Critical Limb Ischemia (CLI) Interventions:
21
LIfeCell LLC, USA
Other: Mesenchymal stem cells from adipose tissue
To Evaluate the Safety and Efficacy of IM and IV Administration of Autologous ADMSCs for Treatment of CLI Interventions:
20
BMMNC
Critical Limb Ischemia
Safety Study of Bone Marrow Cell Concentrate Prepared Using the Magellan System to Treat Critical Limb Ischemia (CLI) Intervention:
19
II
Biological: ACP injections
Side Effects of 4 Times Bone Marrow Mono Nuclear Transplantation in Patients With Ischemic Lower Limb Interventions:
18
Spain
Critical Limb Ischemia
A Clinical Trial on Diabetic Foot Using Peripheral Blood Derived Stem Cells for Treating Critical Limb Ischemia Interventions:
17
BMMNC
Drug: Autologous adipose derived mesenchymal stem cells
Efficacy and Safety Study of NV1FGF in Patients With Severe Peripheral Artery Occlusive Disease. Intervention:
16
II
Autologous Bone Marrow Stem Cell Transfer in Patients With Chronical Critical Limb Ischemia and Diabetic Foot
Intervention: 15
Atsrom Bioscience
Critical Limb Ischemia (CLI); Diabetes
Treatment CLI Nonrevascularizable Lower Limb With Cell Therapy Intervention:
BMMNC
Biological: ASCT01 (Autologous Stem Cell Transplantation)
A Clinical Trial to Study the Efficacy and Safety of Different Doses of Bone Marrow Derived Mesenchymal Stem Cells in Interventions:
III
Critical Limb Ischemia
Induced Wound Healing by Application of Expanded Bone Marrow Stem Cells in Diabetic Patients With Critical Limb Interventions:
Thailan
Other: Intraarterial Infusion of Autologous Bone Marrow Mononuclear Cells
Autologous Endothelial Progenitor Cells (EPCs) From Peripheral Blood in the Treatment of Critical Limb Ischemia Condition:
PBMNC
Critical Limb Ischemia (CLI)
Application of Cell Regeneration Therapy With Mesenchymal Stem Cells From Adipose Tissue in Critical Chronic Intervention:
I
Biological: Ixmyelocel-T; Other: Vehicle Control
Autologous Angiogenic Cell Precursors (ACPs) for the Treatment of Peripheral Artery Disease Intervention:
Spain
Critical Limb Ischemia
Human Adipose Derived Mesenchymal Stem Cells for Critical Limb Ischemia (CLI) in Diabetic Patients Intervention:
BMMNC
Procedure: Angiogenic Cell Precursors (ACPs) or Vescell TM
Study to Assess Efficacy and Safety of Bone Marrow Derived Stem Cells in Patients With Critical Limb Ischemia Intervention:
II
Peripheral Arterial Disease; Critical Limb Ischemia
Intra-‐arterial Infusion of Autologous Bone Marrow Mononuclear Cells in Non-‐diabetic Patients With Critical Limb Intervention:
Czech republic
Other: Intraarterial infusion of autologous bone marrow cells
An Efficacy and Safety Study of Ixmyelocel-‐T in Patients With Critical Limb Ischemia (CLI) Interventions:
State
BMMNC
Arterial Occlusive Disease (CLI); Diabetic Foot
ACPs in Severe PAD/CLI by Direct Intramuscular Injection Intervention:
Product
III
Procedure: Group A: Intramuscular; Procedure: Group B: Intraarterial; Procedure: Group C: Intravenous; Device: Group D: Surgical endovascular treatment with maximum medicamentous treatment
Intraarterial Infusion of Autologous Bone Marrow in Diabetic Patients With Chronic Ischemia of Lower Limbs (CLI) no Intervention:
Clinical Phase
Critical Lower Limb Ischemia; Type-2 Diabetes Mellitus
Critical Leg Ischemia Procedure: cell therapy
Intra-‐arterial Stem Cell Therapy for Patients With Chronic Limb Ischemia (CLI)
35
Completed
36
Recruiting
Conditions: Interventions: Condition: Intervention: 37
Unknown †
Conditions: Completed
Condition: Completed
Conditions: 40
Terminated
Condition: 41
Unknown †
Condition: Interventions: 43
Unknown †
Interventions: 44
Completed
Condition:
University of Wisconsin
II
MSC
Stempeutics Research
II
HGF plasmid
AnGES
I
BIWH3
Bohringer Ingelheim
II
Endometrial
Medistem
II
NL003gen
Beijing
II
ASC-‐MSC
K-‐Stemcell Co
Drug: mesenchymal stem cells; Drug: Plasmalyte A Arterial Occlusive Disease; Peripheral Vascular Disease; Ischemia Genetic: HGF plasmid
Peripheral Arterial Disease Drug: BIWH 3; Drug: Placebo Peripheral Vascular Diseases Biological: Administration of ERC Drug: captopril plus placebo; Drug: telmisartan plus placebo; Drug: Telmisartan plus Captopril; Drug: Placebo Ischemia; Pathologic Processes Genetic: NL003; Other: Normal Saline
Safety and Effect of Adipose Tissue Derived Mesenchymal Stem Cells Implantation in Patients With Critical Limb Ischemia Intervention:
CD133+
Critical Limb Ischemia
Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia Conditions:
I
Biological: autologous CD133+ cells
Phase I/II Trial of Endometrial Regenerative Cells (ERC) in Patients With Critical Limb Ischemia Intervention:
Indianapolis
Critical Limb Ischemia; Arterial Occlusive Disease; Vascular Diseases
Investigation of Safety, Pharmacokinetics and Pharmacodynamics of Different Doses of BIWH 3 in Patients With Chronic Critical Limb Ischaemia Interventions:
ADSC-‐SVF
Device: TGI SVF material via intramuscular injection
Study of HGF Via Plasmid Vector to Improve Perfusion in Critical Limb Ischemia Intervention:
II
Critical Limb Ischemia
Mesenchymal Stem Cells in Critical Limb Ischemia Interventions:
39
Procedure: Bone marrow punction; Procedure: BM-MNC infusion; Procedure: Placebo infusion
Safety Study of Adult Stem Cells to Treat Patients With Severe Leg Artery Disease Intervention:
38
Peripheral Vascular Diseases; Arterial Occlusive Diseases; Leg Ulcer; Gangrene; Ischemia
Evaluation of the Tissue Genesis® Icellator Cell Isolation System™ to Treat Critical Limb Ischemia
Critical Limb Ischemia Procedure: Autologous Adipose Tissue derived MSCs Transplantation